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Background. This study gives an overview of a decade (2007–2017) of hospital-based Salmonella Typhi bloodstream infection 
(BSI) surveillance in the Democratic Republic of the Congo (DRC), at 4 main sampling sites.
Methods. Blood cultures were sampled in hospital-admitted patients with suspected BSI, according to standardized clinical 
indications. The results of the surveillance period 2015–2017 were compiled with those of previous surveillance periods (2007–2010 
and 2011–2014). Whole genome sequencing of isolates with decreased ciprofloxacin susceptibility (DCS) was performed.
Results. Salmonella Typhi was isolated in 1.4% (531/37 388) and 10.3% (531/5177) of suspected and culture-confirmed BSI 
episodes, respectively. Salmonella Typhi ranked first among the BSI pathogens in adults (n = 220), but was mostly (n = 301 [56.7%]) 
isolated from children, of which 72.1% (217/301) and 31.6% (95/301) were <10  years and <5  years old, respectively. Multidrug 
resistance (MDR), DCS, and combined MDR/DCS were found in 38.3% (n = 180), 24.5% (n = 115), and 11.9% (n = 56) of 470 first 
isolates, respectively. MDR and DCS rates had increased since 2007, but remained stable during 2015–2017 with no geographical 
clustering at the province level. Most (91/93 [97.8%]) DCS isolates sequenced belonged to Genotyphi genotype 2.5.1, and gyr S83 
was the most frequent DCS mutation (76/93 [81.7%]). Infections occurred perennially, but increased during the rainy season.
Conclusions. Salmonella Typhi was a frequent cause of BSI in adults and children in DRC, with high rates of antibiotic resis-
tance. Sustainable surveillance and implementation of vaccination are compelling.
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Typhoid fever is a poverty-related disease with a high disease 
burden in low- and middle-income countries [1, 2]. Its caus-
ative organism—Salmonella enterica subspecies enterica sero-
var Typhi—has been listed on the World Health Organization 
(WHO) priority list of antibiotic-resistant bacteria [3]. Recent 
studies have confirmed high incidence rates of typhoid fever 
in sub-Saharan Africa, which have incited vaccination efforts 
[4–6]. Central Africa has been estimated to face the worldwide 
highest incidence of typhoid fever [7]. As to the Democratic 
Republic of the Congo (DRC), the country’s poor infrastructure 
and health services (Supplementary Table 1) make it vulnerable 
to typhoid fever, and clinical and epidemiological observations 
have confirmed its frequency and impact [8, 9]. In the after-
math of the typhoid fever peritonitis outbreak in 2005 [8], the 
National Institute of Biomedical Research (INRB) in Kinshasa 
started, in collaboration with the Institute of Tropical Medicine 
(ITM) in Antwerp, Belgium, a microbiological surveillance in 
sentinel hospitals around the country with the initial objectives 
to investigate and confirm epidemic alerts of typhoid fever and 
to assess the antibiotic resistance of Salmonella Typhi [10, 11].
The present study reports, for the period 2007–2017 in 
DRC, the cumulative temporal, spatial, and age distributions 
of Salmonella Typhi blood culture isolates, their antimicrobial 
resistance patterns, and their genetic relatedness to the global 
Salmonella Typhi population.
METHODS
Microbiology Surveillance Network in DRC
Blood cultures were collected and processed free of charge in 
healthcare facilities in the capital, Kinshasa, and the Bas-Congo 
province (referral hospital of Kisantu) and later extended to 
sentinel hospitals in the Oriental Province (University Hospital 
Kisangani with affiliated hospitals and health centers) and 
the Equateur Province (referral hospital of Bwamanda). Over 
the years, this network was extended with other partners, and 
blood cultures were also added to the diagnostic tools of the 
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Ministry of Health. Indications of blood culture sampling were, 
outside the neonatal period, a body temperature of ≥38.0°C or 
≤35.5°C (axillary) or history of fever during the last 48 hours 
and/or (1) signs of severity such as hypotension, confusion, 
or increased respiratory rate; (2) suspicion of severe local-
ized infections (pneumonia, meningitis, complicated urinary 
tract infection, osteomyelitis and arthritis, severe skin and 
soft tissue infections, gynecological and abdominal infections/
peritonitis); or (3) suspicion of other severe infection: sepsis, 
typhoid fever, and severe malaria. Basic demographic and clin-
ical data were recorded. In adults, blood cultures consisted of 
2 × 10 mL of blood sampled in aerobic BACT/ALERT bottles 
(bioMérieux, Marcy-L’Etoile, France); for children (defined 
as ≤14  years old), 1–4  mL was sampled in pediatric BACT/
ALERT bottles. Grown blood cultures were worked up for iden-
tification according to conventional biochemical methods and 
serotyping (for antibiotic susceptibility testing, see below). For 
reasons of integration in clinical care and capacity building, 
blood cultures were preferentially worked up in the participat-
ing referral hospitals. However, when no competent laboratory 
services were available, samples were transported to INRB for 
workup. Isolates were stored for in-depth reference testing, 
and the results of the blood culture isolates and their resistance 
patterns were registered. Coagulase-negative Staphylococcus, 
Corynebacterium species, Micrococcus species, Cutibacterium 
species, and Lactobacillus species were considered as environ-
mental or skin contaminants; the other bacteria were classi-
fied as pathogens. The term “suspected bloodstream infection 
(BSI) episode” was used to indicate all blood cultures in a single 
patient sampled within a 2-week period according to the indica-
tions mentioned above. A BSI episode was considered as culture 
confirmed when a pathogen was isolated in at least 1 of the bot-
tles. Supplementary Document 1 provides a detailed overview 
of the workflow, criteria, and definitions used in the sampling, 
and the processing and reporting of the blood cultures.
Design of the Present Study
The blood culture isolates from the period January 2015–
October 2017 were retrieved from storage at –80°C and batch-
tested for identification and antibiotic susceptibility. To allow a 
complete 10-year retrospective view, a comprehensive database 
was compiled using the most recent data from 2015–2017 and 
2 databases used for 2 previous Salmonella Typhi reports, com-
prising the periods April 2007–January 2011 (further referred 
to as “2007–2010”) [10] and January 2011–December 2014 
(referred to as “2010–2014”), respectively [11]. The resulting 
database contained all BSI episodes and isolates obtained from 
a 10-year period between April 2007 and October 2017. Part of 
the data were presented in the 2 aforementioned survey reports 
[10, 11], as well as in reports of outbreak publications [10–15]. 
In addition to the methods described in Supplementary Box 
1, detailed data of rainfall were retrieved for the entire study 
period, and additional molecular analysis of the DCS-associated 
factors and genetic typing of the isolates was performed (see 
“Molecular Analysis” below).
Antibiotic Susceptibility Testing
Antibiotic susceptibility testing was carried out on the 2015–2017 
isolates as described in Supplementary Document 1 with slight 
modifications. In brief, disk diffusion was performed with the excep-
tion of minimum inhibitory concentration (MIC) values testing for 
ciprofloxacin and azithromycin, for which the E-test macromethod 
(bioMérieux) was used [16]. Intermediate-susceptible isolates are 
grouped together with the resistant ones [17]. Where applicable, the 
databases of previous reports [10, 11] were reinterpreted according 
to the current guidelines of the Clinical and Laboratory Standards 
Institute (document M100-S28) [16]. Multidrug resistance (MDR) 
refers to the combined resistance to amoxicillin, chloramphenicol, 
and trimethoprim-sulfamethoxazole, and decreased ciprofloxacin 
susceptibility (DCS) refers to ciprofloxacin MIC values >0.06 mg/L 
and <1 mg/L. The term “full ciprofloxacin resistance” was reserved 
for MIC values ≥1 mg/mL [1, 16] and resistance to azithromycin 
was defined at MIC values >16 mg/L [16].
Geographic Data and Data About Rainfall
In 2015, the 11 DRC provinces were split into the actual 26 
provinces; for convenience of data display and comparison with 
previous publications, the former provinces were still used as 
the reference.
Satellite-based remote sensing techniques (Tropical Rainfall 
Measuring Mission [TRMM] data used for TRMM multisatellite 
precipitation analysis, Near Real-Time product version 7) were 
used to estimate the average accumulated monthly rainfall in 
millimeters per month [18]. Datasets can be accessed at https://
disc-beta.gsfc.nasa.gov/. Calculations were performed using 
the R open source software (release 3.3.2) and linked to the 
actual provinces based on spatial data from the Royal Museum 
for Central Africa (Tervuren, Belgium). To obtain the monthly 
rainfall for the former provinces Equateur and Orientale, the 
average of the involved actual provinces was used.
Molecular Analysis
DNA was extracted from the Salmonella Typhi isolates showing DCS 
and listed in Supplementary Table 2, using the Gentra PureGene 
Yeast/Bact Kit (Qiagen, Hilden, Germany) following the manufac-
turer’s guidelines, and whole genome sequencing was performed 
on an Illumina HiSeq platform (Illumina, San Diego, California). 
The sequencing data generated in this study (89 isolates) are avail-
able at the European Nucleotide Archive under the study accession 
number ERP109963. Four Salmonella Typhi had been sequenced 
in previous studies and the sequencing data are available under the 
sample accession numbers ERR349525, ERR352599, ERR357591 
and PRJEB19771 [12, 19]. Molecular resistance mechanisms were 
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version 2.11.1 [20] with the Comprehensive Antibiotic Resistance 
Database version 2.0.2 [21]. Both known and novel variants of 
gyr and par genes conferring DCS were determined. Genome 
assemblies, constructed using de novo assembly [22], were used to 
determine the Salmonella Typhi Genotyphi genotype. Hereto, the 
Genotyphi implementation [23] or Pathogenwatch (https://patho-
gen.watch; Wellcome Trust Sanger Institute, Hinxton, Cambridge, 
United Kingdom) was used.
Statistical Analysis
Unless otherwise stated, analysis and reporting were done for 
the first isolate per BSI episode and for those isolates that were 
available for reference testing at INRB/ITM. Statistical analysis 
was done with Stata software, version 12 (Stata Corp, College 
Station, Texas). Proportions were tested for significance using 
the χ2 test and differences in age distribution by the Wilcoxon-
Mann-Whitney nonparametric test and the median test.
Ethical Considerations
Ethical approval for the microbiological surveillance study was granted 
by the Institutional Review Board of ITM, the Ethics Committee of 
Antwerp University, and the Ministry of Health of the DRC.
RESULTS
Overview of Sampling
For the entire period (2007–2017), blood cultures sampled in 
37  388 BSI episodes yielded 13.9% pathogens; for the period 
2015–2017, the corresponding data were 13  657 and 12.0% 
(Figure 1). Yields of pathogens over time and sampling site 
were mostly between 10.0% and 15.0%. The highest yield 
(24.3%, Equateur 2011–2014) was associated with an outbreak 
of non-Typhi Salmonella infection [13]. The overall contami-
nation rate was 9.2%; for the period 2015–2017, it was 7.17% 
with the lowest and highest rates at the sampling site Kisantu 
Hospital (Bas-Congo, 6.2%) and the surveillance network in 
Kinshasa (16.4%), respectively. Figure 2 shows the provinces 
of DRC with the main sampling sites and total numbers of 
Salmonella Typhi and non-Typhi isolates.
Overall, 4 of 5 suspected BSI episodes occurred in children 
(80.6% among 36.643 episodes for which data about age and year 
of sampling were available). The proportion of BSI episodes in 
children increased over time from 60.5% (5684/9398) in 2007–
2010 to 90.2% (12 188/13 519) in 2015–2017, mainly by higher 
numbers of children sampled but—to a lesser extent—also due 
to lower numbers of adults sampled (1331 in 2015–2017 vs 2045 
and 3714 in 2011–2014 and 2007–2010, respectively).
Proportions of Salmonella Typhi Among Grown Blood Cultures
Overall, Salmonella Typhi accounted for 1.4% (531/37  388) 
and 10.3% (531/5177) of suspected and confirmed BSI, respec-
tively (Figure 1). Among adults, Salmonella Typhi consistently 
ranked first among the pathogens recovered, representing 
24.6% (110/447), 22.9% (67/293), and 24.3% (42/173) for the 
successive surveillance periods. Among the pathogens isolated 
Figure 1. Breakdown of blood cultures sampled as part of the surveillance network, 2007–2017; unless otherwise stated, data are presented as first isolates per blood-
stream infection episode (all blood cultures in a single patient within a 2-week period). In the top 5 of pathogens, the percentages represent the proportion of all pathogens 
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from children, the proportion of Salmonella Typhi was lower—
that is, 7.2% overall (Figure 1) and 11.4% (107/943), 7.1% 
(126/1774), and 4.7% (68/1442) for the successive surveillance 
periods. When subtracting neonates, the overall proportion 
of Salmonella Typhi among the pathogens increased to 7.8% 
(300/3831). Salmonella Typhi ranked third and second in fre-
quency among pathogens isolated from children in Bas-Congo 
and Equateur, respectively. Non-Typhi Salmonella ranked first 
at all but 1 (Kinshasa) sampling site.
Absolute numbers of Salmonella Typhi BSI were higher in 
children compared to adults. A total of 531 single isolates of 
Salmonella Typhi were obtained (301 [56.7%] from children 
vs 220 [41.4%] from adults; for 10 isolates no age was available 
[for details about age, see the next section]). Three recurrent 
BSI episodes were identified, occurring in children aged 12, 
15, and 10 years old, respectively, with the recurrent episode 
occurring 3 weeks, 9 weeks, and 3 years after the initial BSI 
episode. A total of 472 (88.9%) of the isolates were available 
for further analysis (with missing isolates randomly distrib-
uted over time and sampling site). The numbers of Salmonella 
Typhi in adults showed little variation over time (Figure 3A), 
apart from small peaks in 2012 and 2015, which were ran-
domly distributed over the sampling sites. The same observa-
tion was made for children; however, the rate of Salmonella 
Typhi vs non-Typhi Salmonella decreased sharply, in partic-
ular during the 2015–2017 surveillance period and mainly 
at the account of an increase of the non-Typhi Salmonella 
(Figure 3B).
Age and Sex of Patients With Salmonella Typhi
Figure 4 and Supplementary Figure 1 show the detailed age dis-
tribution. Absolute numbers of isolates in children were con-
centrated between 2 and 10  years of age and peaked around 
the age of 5. As a proportion of all isolates from BSI episodes, 
the highest rates were observed among children between 5 
and 14 years old (19.9%–47.2%); 72.1% (217/301) and 31.6% 
(95/301) of Salmonella Typhi isolates were obtained in chil-
dren <10 years and <5 years old, respectively, with 10 children 
<1  year old and the youngest 10  days old. The median age 
(interquartile range [IQR]) of patients with Salmonella Typhi 
BSI was 12 (IQR, 6–24) years, which was significantly higher 
than the corresponding data for the non-Typhi Salmonella 
(20 [IQR, 11–36] months) and all other BSI pathogens 
Figure 3. Over-time evolution of the frequency of Salmonella Typhi compared to non-Typhi Salmonella for adults (A) and children aged <15 years (B). The absolute numbers 
of Salmonella Typhi and non-Typhi Salmonella are shown by the blue and orange bars, respectively, and can be read on the left y-axis (note that the y-axis has a different scale 
for adults vs children). The yellow line represents the percentage of Salmonella Typhi vs all Salmonella isolates (Typhi and non-Typhi combined), reflected on the right y-axis.
Figure 2. Map of the Democratic Republic of the Congo, with its (former) provinces, 
the main participating sampling sites in the microbiological surveillance network (call-
outs), and the total numbers of Salmonella Typhi and Salmonella non-Typhi isolates. 
Additional numbers of isolates were 11 and 0, respectively, in Kasai-Occidental, 9 and 
1 in Bandundu, 3 and 2 in Kasai Oriental, and 0 and 2 in Maniema. The new provinces 
are identified by numbers: 1, Nord-Ubangi; 2, Sud-Ubangi; 3, Mongala; 4, Bas-Uele; 5, 
Haut-Uele; 6, Equateur; 7, Tshuapa; 8, Tshopo; 9, Ituri; 10, Nord-Kivu; 11, Mai-Ndombe; 
12, Kasai; 13, Sankuru; 14, Maniema; 15, Sud-Kivu; 16, Kinshasa; 17, Kwilu; 18, 
Kasai-Central; 19, Kasai-Oriental; 20, Lomami; 21, Tanganyika; 22, Kongo-Central; 23, 
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compiled (24 [IQR, 0–132] months) (P <  .001). Median ages 
for Salmonella Typhi BSI were similar for the successive sur-
veillance periods: 15 (IQR, 8–25), 10 (IQR, 5–21), and 10 (IQR, 
5–21) years, respectively.
Seasonality and Rainfall
The rainy season of Kinshasa and Bas-Congo (south of the 
equator) lasted from October through May and from March 
through November for Equateur and Orientale (north of 
the equator), respectively, although for the latter the differ-
ence between the rainy and dry season was less pronounced 
(Figure 5). In all provinces, Salmonella Typhi BSI was more 
frequent at the beginning and during the rainy season. In 
contrast to the nonfluctuating background of all-cause BSI 
in Kinshasa, Orientale, and Equateur, the all-cause BSI in 
Bas-Congo followed a seasonal pattern comparable to that of 
Salmonella Typhi.
Antibiotic Resistance
As a percentage of Salmonella Typhi isolates for which anti-
biotic susceptibility was assessed, MDR was seen in 38.4% 
(n = 180), DCS in 24.5% (n = 115), and MDR combined with 
DCS in 11.9% (n = 56) of isolates, and azithromycin resistance 
was observed in 1 isolate (Table 1). One Salmonella Typhi iso-
late showing resistance to third-generation cephalosporins 
was found during an outbreak investigation in the province of 
Bandundu [12]. MDR rates over the successive surveillance peri-
ods were 39.9% (77/193), 36.9% (62/168), and 38.0% (41/108); 
corresponding DCS rates were 14.0% (27/193), 36.3% (61/168), 
and 25.0% (27/108), respectively. There was no apparent geo-
graphical concentration of MDR or DCS isolates. Overall, in 
almost half (204/422 [48.3%]) of the Salmonella Typhi BSI epi-
sodes, antibiotics had been given prior to admission (93/159 
[58.5%], 71/153 [46.4%], and 40/110 [36.4%] for the successive 
surveillance periods). No statistically significant increased rate 
of MDR was observed when prehospital antibiotics were given 
(2015–2017: 38.5% MDR with and 37.7% MDR without prehos-
pital antibiotic use; P = .936, χ2 test). There was a trend toward 
an increased rate of DCS if prehospital antibiotics had been 
given (2015–2017: 35.0% vs 18.6%; P = .054, χ2 test).
Decreased Ciprofloxacin Susceptibility and Genotyphi Genotype
Figure 6A shows the ciprofloxacin MIC value distribution of the 
Salmonella Typhi isolates from the entire surveillance period. 
No full resistance was noted. A  nonsynonymous mutation in 
the gyrA or gyrB genes was identified for all 93 confirmed DCS 
Salmonella Typhi isolates (Supplementary Table 2), with 1 iso-
late showing 2 nonsynonymous mutations in gyrA. A substitu-
tion of gyrA S83 was seen in 91.7% of isolates (n = 76, of which 
72 were S83F and 4 were S83Y); another 15.1% had a substi-
tution of D87 in gyrA (n = 14, of which 13 were D87G and 1 
was D87Y) and 1.1% showed a novel gyrA A119E substitution. 
A substitution of gyrB E466D and S464Y was each observed in 
1.1% (n = 1). Strikingly, the gyrA S83F substitution resulted in 
higher MIC values (clustering around 0.25 and 0.38 mg/L com-
pared with the substitution at gyrA D87G, which clustered at 
0.094 and 0.125 mg/L; Figure 6B). The majority (97.8 %) of the 
sequenced DCS isolates belonged to Genotyphi genotype 2.5.1, 
whereas 1.1% (n = 1) had genotype 4.3.1 and 1.1% (n = 1) had 
genotype 2.1, also known as lineage H58.
DISCUSSION
This study gives an overview of Salmonella Typhi BSI in the light 
of a decade of microbiological surveillance in DRC, a country 
where diagnostic microbiological facilities are almost nonex-
istent [24]. The embedment in the routine patient manage-
ment in a low-resource setting faced the well-known technical, 
Figure 4. Distribution of Salmonella Typhi bloodstream infection episodes per age category (A) and per year of age for children (B), in absolute numbers (bars) and as a 
percentage of the total number of pathogens from patients with the same age (shown at top of bars). Data were generated for a total of 519 of 531 episodes for which data 
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logistical, and human resource problems [25, 26]. Furthermore, 
accessibility, local needs of patient care, and security concerns 
directed the selection of the healthcare facilities. Besides rep-
resentativeness and coverage, the healthcare facility–based 
approach had other limitations. Most important, it was not 
possible to calculate and monitor population-based incidence 
in the absence of solid demographic data (census, health utiliza-
tion data) [4, 6]. Second, sampling and laboratory workup were 
done by local staff and may have accounted for higher rates of 
contaminants and more missing data compared to a research 
setting. Finally, the health facility–based approach was depen-
dent on the health-seeking behavior and the referral itinerary 
of patients with a consequently low spatial resolution (presently 
limited to the health center or village level).
As to its strengths, the healthcare facility surveillance 
approach was free of charge for patients and integrated in clin-
ical care. This allowed us to reach many patients in a clinical 
context and was a most cost-effective strategy to obtain a con-
sistently large number of isolates—among them also those of 
other bacterial species. The INRB team managed to maintain 
the network over a long time period, with a high proportion 
of isolates available for reference testing. Despite a too high 
contamination rate (9%), the pathogen rate remained high and 
within the expected ranges over time and site.
Salmonella Typhi consistently ranked first as the cause of BSI 
in adults, indicative of its frequent occurrence of typhoid fever 
in the population, as laboratory-confirmed Salmonella Typhi in 
hospital admitted patients represent only a small fraction of all 
cases [27]. Despite the overrepresentation of children sampled, 
Salmonella Typhi accounted for 7.2% of BSIs in children, most 
of them in the first decade of life, comparable to recent obser-
vations in East and West Africa [5, 28]. The predominance of 
Salmonella Typhi in young children highlights the importance 
of identifying the most effective vaccination strategy. Since 
March 2018, the WHO has recommended the new typhoid con-
jugate vaccine for single-dose immunization of children from 
6 months of age onward [29]. Although typhoid fever occurred 
perennially, there was a seasonal trend with a moderate increase 
in the rainy season as previously described in other African 
countries [30, 31]. The contamination of surface and drinking 
water is the most plausible explanation, although the compo-
nent of malnutrition, which in DRC occurs mainly during the 
rainy season [32], might play a role.
MDR and DCS were found in approximately 1 of 3 and 4 
isolates, respectively; 1 in 8 isolates showed combined DCS 
and MDR. After an increase of DCS in 2011–2014 compared 
to 2007–2010, the rate of DCS slightly decreased (24.6%). 
The rate of MDR remained stable in 2015–2017 (37.9%). The 
observed MIC values for gyrA substitutions are comparable to 
those previously published from Asia [33, 34]. The frequency of 
antimicrobial resistance was high and widespread, with no geo-
graphical clustering on province level. Of note, the Salmonella 
Typhi with MDR and cephalosporin resistance previously 
reported from the DRC belonged to the same clade (genotype 
2.5.1) as the majority of the presently assessed DCS isolates, 
which highlights the relevance of ongoing surveillance and the 
implementation of vaccination [12].
Figure 5. Relation between rainfall and frequency of Salmonella Typhi blood-
stream infection in a rural area north (Orientale and Equateur, A) and south (Bas-
Congo, B) of the equator, and an urban area (Kinshasa, C). The average rainfall for 
the 10-year surveillance period is displayed as gray bars and expressed in millime-
ters per month (left y-axis), the average numbers of Salmonella Typhi isolates (blue 
line), and bloodstream infection episodes caused by all pathogens (red line) per 
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In conclusion, the established microbiological surveillance 
network and the high numbers of Salmonella Typhi BSI epi-
sodes in children elicit the DRC as a candidate to study the effi-
cacy of the introduction of the typhoid conjugate vaccine [4]. 
MDR and DCS remained a major threat over the whole decade 
and warrant sustainable surveillance efforts [35].
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ent_2/S130/5371237 by guest on 08 M
arch 2019
Salmonella Typhi Surveillance in DRC • CID 2019:68 (Suppl 2) • S137
3. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of 
new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuber-
culosis. Lancet Infect Dis 2017; 3099:1–10.
4. Marks F, von Kalckreuth V, Aaby P, et al. Incidence of invasive Salmonella disease 
in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet 
Glob Health 2017; 5:e310–23.
5. Jeon  HJ, Pak  GD, Im  J, et  al. Determining the best immunization strategy for 
protecting African children against invasive Salmonella disease. Clin Infect Dis 
2018; 67:1824–30.
6. Guiraud I, Post A, Diallo SN, et al. Population-based incidence, seasonality and 
serotype distribution of invasive salmonellosis among children in Nanoro, rural 
Burkina Faso. PLoS One 2017; 12:1–17.
7. Antillón M, Warren JL, Crawford FW, et al. The burden of typhoid fever in low- 
and middle-income countries: a meta-regression approach. PLoS Negl Trop Dis 
2017; 11:1–21.
8. Muyembe-Tamfum JJ, Veyi J, Kaswa M, Lunguya O, Verhaegen J, Boelaert M. 
An outbreak of peritonitis caused by multidrug-resistant Salmonella Typhi in 
Kinshasa, Democratic Republic of Congo. Travel Med Infect Dis 2009; 7:40–43.
9. Ali  E, Van  Den  Bergh  R, D’hondt  R, et  al. Localised transmission hotspots of 
a typhoid fever outbreak in the Democratic Republic of Congo. Pan Afr Med J 
2017; 28:1–9.
10. Lunguya  O, Lejon  V, Phoba  MF, et  al. Salmonella Typhi in the Democratic 
Republic of the Congo: fluoroquinolone decreased susceptibility on the rise. PLoS 
Negl Trop Dis 2012; 6:3–8.
11. Kalonji LM, Post A, Phoba MF, et al. Invasive Salmonella infections at multiple 
surveillance sites in the Democratic Republic of the Congo, 2011–2014. Clin 
Infect Dis 2015; 61:S346–53.
12. Phoba M-F, Barbé B, Lunguya O, et al. Salmonella enterica serovar Typhi produc-
ing CTX-M-15 extended spectrum β-lactamase in the Democratic Republic of 
the Congo. Clin Infect Dis 2017; 65:1229–31.
13. Phoba MF, De Boeck H, Ifeka BB, et al. Epidemic increase in Salmonella blood-
stream infection in children, Bwamanda, the Democratic Republic of Congo. Eur 
J Clin Microbiol Infect Dis 2014; 33:79–87.
14. Phoba M-F, Lunguya O, Mayimon DV, et al. Multidrug-resistant Salmonella enter-
ica, Democratic Republic of the Congo. Emerg Infect Dis 2012; 18:1692–4.
15. Falay  D, Kuijpers  LMF, Phoba  MF, et  al. Microbiological, clinical and molecu-
lar findings of non-typhoidal Salmonella bloodstream infections associated with 
malaria, Oriental Province, Democratic Republic of the Congo. BMC Infect Dis 
2016; 16:271.
16. Clinical and Laboratory Standards Institute. Performance standards for antimi-
crobial susceptibility testing. Wayne, PA: CLSI, 2018.
17. Clinical and Laboratory Standards Institute. M39-A4 analysis and presentation 
of cumulative antimicrobial susceptibility test data; approved guideline, 4th ed. 
Wayne, PA: CLSI, 2014.
18. Huffman GJ, Bolvin DT, Nelkin EJ, et al. The TRMM multisatellite precipitation 
analysis (TMPA): quasi-global, multiyear, combined-sensor precipitation esti-
mates at fine scales. J Hydrometeorol 2007; 8:38–55.
19. Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant 
multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracon-
tinental transmission events. Nat Genet 2015; 47:632–9.
20. Hunt M, Mather AE, Sánchez-Busó L, et al. ARIBA: rapid antimicrobial resistance 
genotyping directly from sequencing reads. Microb Genomics 2017; 3:e000131.
21. McArthur AG, Waglechner N, Nizam F, et al. The comprehensive antibiotic resis-
tance database. Antimicrob Agents Chemother 2013; 57:3348–57.
22. Page AJ, De Silva N, Hunt M, et al. Robust high-throughput prokaryote de novo 
assembly and improvement pipeline for Illumina data. Microb Genom 2016; 
2:e000083.
23. Wong VK, Baker S, Connor TR, et al. An extended genotyping framework for 
Salmonella enterica serovar Typhi, the cause of human typhoid. Nat Commun 
2016; 7:12827.
24. Lunguya  O, Phoba  MF, Mundeke  SA, et  al. The diagnosis of typhoid fever 
in the Democratic Republic of the Congo. Trans R Soc Trop Med Hyg 2012; 
106:348–55.
25. Barbé B, Yansouni CP, Affolabi D, Jacobs J. Implementation of quality manage-
ment for clinical bacteriology in low-resource settings. Clin Microbiol Infect 
2017; 23:426–33.
26. Ombelet S, Ronat JB, Walsh T, et al. Clinical bacteriology in low-resource settings: 
today’s solutions. Lancet Infect Dis 2018; 3099:1–11.
27. Crump JA, Youssef FG, Luby SP, et al. Estimating the incidence of typhoid fever 
and other febrile illnesses in developing countries. Emerg Infect Dis 2003; 
9:539–44.
28. Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income 
and middle-income countries: a systematic, literature-based update with risk-fac-
tor adjustment. Lancet Glob Health 2014; 2:e570–80.
29. World Health Organization. Typhoid vaccines: WHO position paper, March 
2018—recommendations. Vaccine 2018; 153–72.
30. Labi A-K, Obeng-Nkrumah N, Addison NO, Donkor ES, Donkor ES. Salmonella 
blood stream infections in a tertiary care setting in Ghana. BMC Infect Dis 2014; 
14:3857.
31. Breiman RF, Cosmas L, Njuguna H, et al. Population-based incidence of typhoid 
fever in an urban informal settlement and a rural area in Kenya: implications for 
typhoid vaccine use in Africa. PLoS One 2012; 7.
32. Kismul H, Schwinger C, Chhagan M, Mapatano M, Van den Broeck J. Incidence 
and course of child malnutrition according to clinical or anthropometrical assess-
ment: a longitudinal study from rural DR Congo. BMC Pediatr 2014; 14:22.
33. Chau  TT, Campbell  JI, Galindo  CM, et  al. Antimicrobial drug resistance of 
Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced 
susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 2007; 
51:4315–23.
34. Parry  CM, Thuy  CT, Dongol  S, et  al. Suitable disk antimicrobial susceptibility 
breakpoints defining Salmonella enterica serovar Typhi isolates with reduced sus-
ceptibility to fluoroquinolones. Antimicrob Agents Chemother 2010; 54:5201–8.
35. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal 







ent_2/S130/5371237 by guest on 08 M
arch 2019
